STOCK TITAN

Curanex Pharmaceuticals (CURX) Financials

CURX NASDAQ
Trailing 12 months to September 30, 2026
Revenue Not reported for the trailing 12 months
Net Income -$12.3M n/m YoY
EPS (Diluted) -$8.86 YoY not available
Operating Cash Flow -$4.3M n/m YoY
Market Cap $6.9M as of Nov 20, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 2.7x on $2.5M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CURX SEC filings page.

This page shows Curanex Pharmaceuticals Inc (CURX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CURX FY2025

FY2025 shows a development-stage business where research spending and cash financing, rather than revenue, currently determine the operating profile.

FY2025’s net loss was $4.23M, while operating cash flow was -$10.5M, so cash use substantially exceeded the reported loss. Financing cash flow reached $15.3M, indicating external funding—not operating receipts—financed the period’s balance-sheet expansion.

With no reported revenue and R&D spending of $2.99M against SG&A of $1.25M, FY2025 spending is centered more on development than general administration. That combination explains why profitability metrics are currently negative without creating a conventional sales-margin story.

Assets expanded 2135.8% while liabilities expanded 2377.1%, reflecting a much larger balance sheet in FY2025. Liabilities were 3.1% of assets versus 2.8% in FY2024, leaving the company predominantly equity-funded rather than debt-funded.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Curanex Pharmaceuticals Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
2/6

Curanex Pharmaceuticals Inc passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing
N/A

Curanex Pharmaceuticals Inc reported a net loss of $4.2M while operations used $10.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Curanex Pharmaceuticals Inc reported an operating loss of $4.2M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income
-$2.8M
YoYn/m
QoQn/m

Curanex Pharmaceuticals Inc reported a net loss of $2.8M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$1.86
YoYn/m
QoQn/m

Curanex Pharmaceuticals Inc earned -$1.86 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt
$1.6M
YoY-72.8%
QoQ-46.2%

Curanex Pharmaceuticals Inc held $1.6M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
2M
YoY+10.7%
QoQ0.0%

Curanex Pharmaceuticals Inc had 2M shares outstanding in Q3 2026. This represents an increase of 10.7% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-110.6%
YoY-103.9pp
QoQ-41.9pp

Curanex Pharmaceuticals Inc's quarterly ROE was -110.6% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 103.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 41.9 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$2.0M
YoY+188.2%
QoQ-24.7%

Curanex Pharmaceuticals Inc invested $2.0M in research and development in Q3 2026. This represents an increase of 188.2% from the same quarter a year earlier. Against the prior quarter it is down 24.7%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

CURX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CURX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
R&D Expenses$2.0M+188.2%$2.6M$2.3MN/A$677KN/AN/AN/A
SG&A Expenses$877K+220.3%$732K+1169.3%$927K+574.6%N/A$274K+193.5%$58K+30.4%$137KN/A
Operating Income-$2.8Mn/m-$3.3Mn/m-$3.2Mn/m-$3.1M-$951Kn/m-$58Kn/m-$137KN/A
Interest ExpenseN/AN/AN/A$0$4K$3K$1KN/A
Net Income-$2.8Mn/m-$3.3Mn/m-$3.2Mn/m-$3.1Mn/m-$954Kn/m-$60Kn/m-$138Kn/m-$146K
EPS (Basic)-$1.86n/m-$2.40n/m-$2.20n/m-$2.40-$0.75$0.00-$0.20N/A
EPS (Diluted)-$1.86n/m-$2.40n/m-$2.20n/m-$2.40-$0.75$0.00-$0.20N/A
Diluted Shares (Avg)2M+18.5%1M+18.2%1M+18.1%N/A1M1M1MN/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.

CURX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CURX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'25FilingQ1'2510-QQ4'2410-K
Total Assets$3.1M-78.6%$5.1M+544.6%$8.4M$11.6M+2135.8%$14.5M$787KN/A$518K
Current Assets$2.6M-82.3%$4.8M+573.8%$8.1M$11.2M+2067.7%$14.4M$711KN/A$518K
Cash & Equivalents$1.6M-72.8%$2.9M+2599.3%$4.0M$5.0M+3258.2%$5.8M$109KN/A$149K
Short-Term Investments$0n/m$0n/m$0$0n/m$0$0N/A$0
Long-Term Investments$0n/m$0n/m$0$0n/m$0$0N/A$0
Total Liabilities$552K+196.8%$286K-40.6%$333K$361K+2377.1%$186K$482KN/A$15K
Current Liabilities$143K-22.9%$104K+37.4%$129K$137K+840.2%$186K$76KN/A$15K
Non-Current Liabilities$409Kn/m$182K-55.2%$204K$224Kn/m$0$406KN/A$0
Total Equity$2.5M-82.2%$4.8M+1467.5%$8.1M+2108.6%$11.2M+2128.8%$14.3M+2189.8%$305K-57.3%$366K+181.6%$503K
Retained Earnings-$14.1Mn/m-$11.3Mn/m-$8.0M-$4.8Mn/m-$1.8M-$820KN/A-$622K

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

CURX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CURX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$1.4Mn/m-$1.1Mn/m-$955Kn/m-$857Kn/m-$9.2Mn/m-$290K-$150K-$95K
Stock-Based Compensation$154KN/A$10KN/AN/AN/AN/AN/A
Financing Cash FlowN/AN/AN/A$0n/m$14.9Mn/m$200K$200K$0

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

CURX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CURX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-110.6%-103.9pp-68.7%-49.0pp-39.0%-1.4pp-27.4%+1.6pp-6.7%+7.9pp-19.8%-13.6pp-37.6%+24.1pp-29.0%
Return on Assets-90.9%-84.3pp-64.9%-57.2pp-37.5%-26.5%+1.6pp-6.6%-7.7%N/A-28.2%
Current Ratio17.84-59.7x45.95+36.6x62.8781.93+46.4x77.539.37N/A35.54
Liabilities-to-Equity0.22+0.2x0.06-1.5x0.040.030.0x0.011.58N/A0.03

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Curanex Pharmaceuticals Inc CURX FY2025 N/A -$4.2M N/A $6.9M —
Alaunos Therapeutics, Inc. TCRT FY2025 $5K -$4.2M N/A $7.0M —
FibroBiologics, Inc. FBLG FY2025 N/A -$18.6M N/A $6.3M —
MetaVia Inc. MTVA FY2025 N/A -$13.0M N/A $6.8M —
GT Biopharma Inc. GTBP FY2025 N/A -$28.4M N/A $6.3M —
Enveric Biosciences, Inc. ENVB FY2025 N/A -$8.8M N/A $6.0M —

Frequently Asked Questions

No, Curanex Pharmaceuticals Inc (CURX) reported a net loss of $12.3M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $4.2M.

Curanex Pharmaceuticals Inc (CURX) reported diluted earnings per share of -$3.40 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Curanex Pharmaceuticals Inc (CURX) has a return on equity of -37.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Curanex Pharmaceuticals Inc (CURX) recorded an outflow of $10.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Curanex Pharmaceuticals Inc (CURX) had $11.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Curanex Pharmaceuticals Inc (CURX) invested $3.0M in research and development during fiscal year 2025.

Curanex Pharmaceuticals Inc (CURX) had 1M shares outstanding as of fiscal year 2025.

Curanex Pharmaceuticals Inc (CURX) had a current ratio of 81.93 as of fiscal year 2025, which is generally considered healthy.

Curanex Pharmaceuticals Inc (CURX) had a liabilities-to-equity ratio of 0.03 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Curanex Pharmaceuticals Inc (CURX) had a return on assets of -36.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Curanex Pharmaceuticals Inc (CURX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $6.9M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Curanex Pharmaceuticals Inc (CURX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $6.9M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Curanex Pharmaceuticals Inc (CURX) held $5.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.5M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Curanex Pharmaceuticals Inc (CURX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $4.2M while operations used $10.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Curanex Pharmaceuticals Inc (CURX) reported an operating loss of $4.2M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top